{"id":1011115,"date":"2026-10-18T09:33:02","date_gmt":"2026-10-18T13:33:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/"},"modified":"2026-10-18T09:33:02","modified_gmt":"2026-10-18T13:33:02","slug":"spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/","title":{"rendered":"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WALTHAM, Mass., Oct.  18, 2026  (GLOBE NEWSWIRE) &#8212; Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre\u2019s IBD antibodies\u2014SPY001 (anti-\u03b14\u03b27), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)\u2014which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms.<\/p>\n<p>\u201cDespite significant advances in the treatment of IBD, many patients still do not achieve or maintain the level of disease control we would like to see, underscoring the need for new approaches that can deliver deeper and more durable responses,\u201d said Silvio Danese, M.D., Ph.D., Professor of Gastroenterology at Vita-Salute San Raffaele University and Head of the Gastroenterology and Endoscopy Unit at IRCCS San Raffaele Hospital in Milan, and Chair of the SKYLINE trial Steering Committee. \u201cWe believe that advanced combination therapy provides a strong probability of enhanced efficacy compared to today\u2019s monotherapies, and Spyre\u2019s approach of combining optimized versions of antibodies against proven targets represents one of the most promising pipelines in the field. With clinical proof-of-concept now demonstrated across SPY001, SPY002 and SPY003, we are increasingly excited to see the combination results next year with the potential to raise the therapeutic ceiling for patients with IBD.\u201d<\/p>\n<p>The poster and presentation will be available for viewing during UEGW, and details are as follows:<\/p>\n<p>\n        <strong>Oral Presentation<\/strong>\n      <\/p>\n<p>\n        <strong>Title<\/strong>: Efficacy and Safety of Half-Life Extended Antibodies SPY001, SPY002, and SPY003 for Induction Treatment of Moderately to Severely Active Ulcerative Colitis<br \/><strong>Abstract Session:<\/strong> Hot Topics in IBD<br \/><strong>Presentation Date\/Time:<\/strong> Sunday, Oct. 18,15:30-15:40 CEST<br \/><strong>Presentation Location:<\/strong> Room B3<br \/><strong>Presenter: <\/strong>Silvio Danese, M.D., Ph.D., San Raffaele Hospital<\/p>\n<p>\n        <strong>Moderated Poster<\/strong>\n      <\/p>\n<p>\n        <strong>Title<\/strong>: Anti-\u03b14\u03b27 integrin, anti-TL1A, and anti-IL-23 are efficacious in TNBS-induced colitis using humanized mice, and combinations further improve efficacy<br \/><strong>Poster Session:<\/strong> New Insights into IBD Biology (II)<br \/><strong>Session Date\/Time:<\/strong> Monday, Oct. 19, 16:06-16:12 CEST<br \/><strong>Presentation Location:<\/strong> Hall 7, Poster Stage 2<br \/><strong>Presenter:<\/strong> Andy Spencer, Ph.D., Spyre Therapeutics<\/p>\n<p>Full session details can be accessed via the UEGW program.<\/p>\n<p>\n        <strong>About Spyre Therapeutics<\/strong>\n      <\/p>\n<p>Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre&#8217;s pipeline includes investigational extended half-life antibodies targeting \u03b14\u03b27, TL1A, IL-23, and IL-17A\/F as well as rational combination programs.<\/p>\n<p>For more information, visit Spyre&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d6z-zutfGkDDsS4rXMRBtwWOZPZBKMgUj1dRvNKe4eBRAZnarfiwEI1c-CD29a46qwj2Q-i9HQjBA-n1mTMApg==\" rel=\"nofollow\" target=\"_blank\">www.spyre.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements in this press release, other than purely historical information, may constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Spyre and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Spyre&#8217;s management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, Spyre\u2019s ability to develop next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the potential of advanced combination therapy to provide enhanced efficacy compared to today\u2019s monotherapies; the potential of combination therapies to raise the therapeutic ceiling for patients with IBD; and Spyre\u2019s clinical development activities, including the expected timing and results of the ongoing SKYLINE Phase 2 platform trial, including timing of data readouts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;opportunity,&#8221; &#8220;potential,&#8221; &#8220;milestones,&#8221; &#8220;pipeline,&#8221; &#8220;can,&#8221; &#8220;goal,&#8221; &#8220;aim,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;anticipate,&#8221; &#8220;achieve,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Spyre will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Spyre&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company\u2019s interpretation of data and the Company\u2019s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described under the heading &#8220;Risk Factors,&#8221; &#8220;Risk Factor Summary&#8221; and &#8220;Note about Forward-Looking Statements&#8221; in Spyre&#8217;s most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that the Company has filed or will file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Spyre from time to time. Should one or more of these risks or uncertainties materialize, or should any of Spyre&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.<\/p>\n<p>\n        <strong>For Investors:<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0 <br \/>Eric McIntyre<br \/>SVP of Finance and Investor Relations<br \/>Spyre Therapeutics<br \/>Eric.mcintyre@spyre.com<\/p>\n<p>\n        <strong>For Media:<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0 <br \/>Josie Butler, 1AB<br \/>josie@1abmedia.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzQ4ZTA0YTItOGI1YS00ODM4LWI1MjUtZGQ3NTY4NWY4ZjEzLTEzMDYzNjMtMjAyNi0xMC0xOC1lbg==\/tiny\/Spyre-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) &#8212; Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre\u2019s IBD antibodies\u2014SPY001 (anti-\u03b14\u03b27), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)\u2014which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms. \u201cDespite significant advances in the treatment of IBD, many patients still do not achieve or &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1011115","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) &#8212; Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre\u2019s IBD antibodies\u2014SPY001 (anti-\u03b14\u03b27), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)\u2014which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms. \u201cDespite significant advances in the treatment of IBD, many patients still do not achieve or &hellip; Continue reading &quot;Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-18T13:33:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026\",\"datePublished\":\"2026-10-18T13:33:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/\"},\"wordCount\":1117,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/\",\"name\":\"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=\",\"datePublished\":\"2026-10-18T13:33:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/","og_locale":"en_US","og_type":"article","og_title":"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 - Market Newsdesk","og_description":"WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) &#8212; Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre\u2019s IBD antibodies\u2014SPY001 (anti-\u03b14\u03b27), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)\u2014which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms. \u201cDespite significant advances in the treatment of IBD, many patients still do not achieve or &hellip; Continue reading \"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-18T13:33:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026","datePublished":"2026-10-18T13:33:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/"},"wordCount":1117,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/","name":"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=","datePublished":"2026-10-18T13:33:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDg2MyM3ODkzMzI3IzIyOTQ4MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-european-gastroenterology-week-uegw-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1011115"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011115\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1011115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1011115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1011115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}